Institute for Human Infections and Immunity,
University of Texas
Hepatitis C virus; Global epidemiology;
www.wjgnet.com
Epidemiology of hepatitis C virus infection
www.wjgnet.com
Scandinavia; the highest prevalence (15%-20%) has been
reported from countries in the United Kingdom and
Northern Africa. The lowest prevalence (0.01%-0.1%) has
rather than individual countries. Region-specific estimates
this estimate is based on weighted averages for regions
worldwide (Figure 1) correspond to about 130 million people, mostly of whom are
chronically infected. HCV-infected people serve as a
reservoir for transmission to others and are at risk for
developing chronic liver disease, cirrhosis, and primary
hepatocellular carcinoma (HCC). It has been estimated
that HCV accounts for 27% of cirrhosis and 25% of
HCC worldwide. HCV infection has likely been endemic
in many populations for centuries. However, the wave
of increased HCV-related morbidity and mortality that
we are now facing is the result of an unprecedented
increase in the spread of HCV during the 20th century.
Two 20th century events appear to be responsible for
this increase; the widespread availability of injectable
therapies and the illicit use of injectable drugs.

© 2007 The WJG Press. All rights reserved.

Key words: Hepatitis C virus; Global epidemiology;
Incidence; Prevalence; Transmission; Natural history

Alter MJ. Epidemiology of hepatitis C virus infection. World
J Gastroenterol 2007; 13(17): 2436-2441

http://www.wjgnet.com/1007-9327/13/2436.asp

PREVALENCE AND INCIDENCE

The estimated global prevalence of HCV infection is 2.2%,
corresponding to about 130 000 000 HCV-positive persons
worldwide (Figure 1). Because many countries lack data,
this estimate is based on weighted averages for regions
rather than individual countries. Region-specific estimates
range from < 1.0% in Northern Europe to > 2.9% in
Northern Africa. The lowest prevalence (0.01%-0.1%) has
been reported from countries in the United Kingdom and
Scandinavia; the highest prevalence (15%-20%) has been
reported from Egypt. An estimated 27% of cirrhosis and
25% of HCC worldwide occur in HCV-infected people.

There are both geographic and temporal differences
in the patterns of HCV infection. For example, vastly
different countries, including the United States, Australia,
Turkey, Spain, Italy, and Japan, belong to regions of the
world with similar overall average prevalences of HCV
infection (1.0%-1.9%), but have different patterns of
age-specific prevalence (Figure 2A). In the United States,
prevalence is highest among persons 30-49 years old,
who account for two-thirds of all infections, and lower
than average among persons less than 20 and greater than
50 years old. This pattern indicates that most HCV
transmission occurred in the last 20-40 years, and primarily
among young adults, a pattern similar to that observed
in Australia. In the United States, Australia, and
countries in western and northern Europe with similar
HCV epidemiology, the greatest variations in prevalence
occur among persons with different risk factors
for infection.

In contrast, the age-specific prevalences of HCV
infection increase steadily with age in Turkey, Spain, Italy,
Japan, and China, (Figure 2A). In these countries,
persons > 50 years old account for most infections,
which suggests a cohort effect in which the risk for HCV
infection was higher in the distant past, i.e., 40-60 years
previously. In many countries with this pattern, the greatest
variations in HCV prevalence occur geographically. In Italy,
Japan, and China, for example, there are hyperendemic
areas of the country in which older persons have an HCV
prevalence 20-fold greater than the average overall and
1.5-2-fold greater than the prevalence among older persons
in other areas of the country.

The highest HCV prevalence in the world occurs in
Egypt, where the prevalence of infection increases steadily
with age, and high rates of infection are observed among
persons in all age groups (Figure 2B). This pattern
indicates an increased risk in the distant past followed by
an ongoing high risk for acquiring HCV infection,
although there are regional differences in average overall
prevalence.

Determining the incidence of HCV infection (i.e., the
rate of newly acquired infections) is difficult because most
acute infections are asymptomatic, available assays do not
distinguish acute from chronic or resolved infection, and
most countries do not systematically collect data on cases
of acute disease. Even in countries with well-established
surveillance systems, acute disease reporting systems
underestimate the incidence of HCV infection. For several countries, mathematical models have been used to infer trends in incidence, which rely on the assumption that current age-specific prevalence reflects the cumulative risk of acquiring infection.

In the United States, trends in HCV incidence were modeled using age-specific incidence from reported cases of acute disease and age-specific prevalence from a cross-sectional national survey. This model showed a large increase in the incidence of newly acquired HCV infections from the late 1960s to the early 1980s. The estimated annual incidence was low (18 per 100,000) before 1965, increased steadily through 1980, and remained high (130 per 100,000) through 1989, corresponding to an average of 240,000 infections per year in the 1980s. Since 1989, the incidence of reported cases of hepatitis C has declined by more than 80%, consistent with the finding that the national seroprevalence of infection remained unchanged between 1988 and 2002. The rate of new HCV infections also declined in Italy in the 1990s according to reported cases of acute disease. In both the United States and Italy, most newly acquired infections are in young adults (30-35 years old). A model of HCV burden in France, which employed death rates from hepatocellular carcinoma in addition to cross-sectional seroprevalence studies to estimate past incidence, showed a trend similar to that of the United States with increasing incidence through the 1980s, whereas an alternative approach to modeling disease burden in Australia showed a steady increase in new HCV infections in that country from 1961-2001.

Several other countries have measured HCV infection incidence by determining the rate of seroconversions in HCV-negative cohorts followed over time. Cohort studies conducted in hyperendemic areas in Taiwan and Japan found incidence rates of HCV infection of 110/10,000 and 28-36/10,000 persons, respectively. The mean age of persons with newly acquired HCV infection was 50 years in the Taiwan cohort and 40 and 60 years, respectively, in the two Japan cohorts. Cohort studies in Egypt found incidence rates of 0.8/1000 person-years in an area of Upper Egypt where the background prevalence was 9% and 6.8/1000 in the Nile Delta where the background prevalence was 24%. Sixty-seven percent of the incident infections were in persons < 20 years old.

Because chronic liver disease may develop many years after infection, the past incidence is a major determinant of the future burden of HCV-associated complications. In the United States and other countries where the emergence of HCV infection is a more recent event, the full magnitude of the burden of HCV-related chronic liver disease has yet to be realized as the duration of infection among most infected persons has not reached the point at which complications from chronic liver disease typically occur. In countries where the emergence of HCV infection occurred in the distant past (such as Japan and Italy), the burden of HCV-related chronic disease already might have reached its highest magnitude, but changes in disease transmission patterns that result in younger persons acquiring infection could result in future increases in chronic disease as this cohort ages.

---

**Figure 1** Estimated HCV prevalence by region.

**Figure 2** Age-Specific prevalence of antibody to hepatitis C virus by selected countries. Numbers in parentheses indicate average regional prevalence in which country resides (see Figure 1).
Table 1  Importance of different exposures to HCV transmission patterns in low, moderate and high prevalence areas worldwide

<table>
<thead>
<tr>
<th>Exposure</th>
<th>The extent exposure contributes to HCV transmission by level of HCV prevalence</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Low</td>
</tr>
<tr>
<td>Injecting drug use</td>
<td>++++</td>
</tr>
<tr>
<td>Transfusions (unscreened)</td>
<td>+++</td>
</tr>
<tr>
<td>Unsafe therapeutic injections</td>
<td>+</td>
</tr>
<tr>
<td>Occupational</td>
<td>+</td>
</tr>
<tr>
<td>Perinatal</td>
<td>+</td>
</tr>
<tr>
<td>High-risk sex</td>
<td>++</td>
</tr>
</tbody>
</table>

there has been an ongoing high risk for decades, the high magnitude of the current burden of HCV-related chronic disease is predicted to continue into the future[57].

MODES OF TRANSMISSION

The most efficient transmission of HCV is through large or repeated direct percutaneous exposures to blood (e.g., transfusion or transplantation from infectious donors, injecting drug use)[10]. HCV is less efficiently transmitted by single small dose percutaneous exposures (e.g., accidental needlesticks)[10,38] or by mucosal exposures to blood or serum-derived fluids (e.g., birth to an infected mother, sex with an infected partner).

There is also evidence that the environment can serve as a reservoir for infectious virus. HCV transmission by inapparent percutaneous exposures has been caused by cross-contamination from reused needles and syringes, multiple-use medication vials, infusion bags, and injecting-drug use paraphernalia[41,42]. These epidemiologic data implicating transmission from environmental sources of HCV are supported by an experimental study that demonstrated the infectivity of HCV in blood after exposure to drying and storage at room temperature[43]. Similar results have been reported for hepatitis B virus (HBV)[44]. However, the risk for transmission of HBV from such inapparent exposures appears to be greater, probably because of differences in characteristics between the two viruses, including the longer environmental survival of HBV[45] and concentrations in the blood of infected persons two- to four-logs higher[46].

However, in the recent cohort study in Egypt, the strongest predictor of incident HCV infection was having an anti-HCV–positive family member[38]. Among those that did, incidence was 5.8/1000 PY compared with 1.0/1000 PY (P < 0.01) among those with no positive family members. The highest incidence rate (14.1/1000 PY) was in children younger than 10 who were living in households with an anti-HCV–positive parent. The study did not determine the factors responsible for this association.

RISK FACTORS

Risk factors associated with acquiring infection as determined from cohort (prospective) and case control (retrospective) studies of persons with acute disease (or infection) have included transfusion of blood and blood products and transplantation of solid organs from infected donors, injecting drug use, unsafe therapeutic injections, occupational exposure to blood (primarily contaminated needle sticks), birth to an infected mother, sex with an infected partner, and sex with multiple partners[9,10]. Among these, transfusion from un-screened donors, injecting drug use, and unsafe therapeutic injections have been the most important, however, there are temporal and geographical differences in the extent to which these risk factors have contributed to HCV transmission (Table 1).

BLOOD TRANSFUSION AND IATROGENIC EXPOSURES

Transfusion-associated HCV infection was a worldwide risk before HCV testing became available. It has been virtually eliminated in those countries that implemented routine HCV testing of donors[40], but in others, receipt of blood transfusions remains an important source for infection. Some countries continue to use commercial donors to supplement their blood supplies, have not considered blood safety a priority, and lack the resources to implement donor screening[47].

Of even greater importance in the spread of HCV, are unsafe therapeutic injections performed by both professionals and non-professionals. It has been estimated that approximately 2 million HCV infections are acquired annually from contaminated health care injections, and may account for up to 40% of all HCV infections worldwide[48]. In many developing countries, supplies of sterile syringes may be inadequate or nonexistent, non-professionals often administer injections outside the medical setting, and injections are often given to deliver medications that could otherwise be delivered by the oral route. Reuse of glass syringes during the early campaign to treat schistosomiasis in Egypt appeared to be responsible for the largest outbreak of iatrogenic transmission of a bloodborne pathogen ever recorded[49]. In addition to unsafe injection practices, lack of attention to appropriate cleaning and disinfection of equipment used in hospital and dental settings also may be a source for HCV transmission.

ILLEGAL INJECTING DRUG USE

Injecting drug use has been the predominant mode of transmission during the past 40 years in the United States and Australia, and now accounts for most newly acquired infections in many other countries, including those in Western, Northern, and Southern Europe. Although cumulative infection rates among young injection drug users during the first 2-3 years of injecting have slowed in recent years, declining from 80% during the late 1980s to 30% during the late 1990s, incidence among new injectors remains high, ranging from 15% to > 30% annually[49]. Fewer sharing partners are necessary to sustain HCV transmission than are necessary for other bloodborne viruses[50], and indirect drug sharing and preparation practices, such as backloading and sharing cotton, cooiker, and rinse water, have been associated with HCV transmission[51]. These results indicate that harm
reduction messages and access to drug treatment need to be expanded to prevent new HCV infections, particularly among young injectors.

OTHER EXPOSURES

In contrast, the contributions of occupational, perinatal, and high-risk sexual exposures have been relatively constant over time and with substantially less geographic variation (Table 1)[52]. The relatively low efficiency of these routes for transmission compared to those involving large or repeated percutaneous exposures may explain these differences.

Occupational transmission of HCV infection is largely confined to health care workers who have sustained contaminated needlestick injuries; average incidence of anti-HCV seroconversion from an HCV-positive source is 1.8%; transmission has been associated with hollow-bore needles and deep injuries[39]. Transmission rarely occurs from mucous membrane or non-intact skin exposures to blood[34], and no transmission to health care workers has been documented from intact skin exposures to blood. Furthermore, the prevalence of HCV infection among health care workers, including orthopedic, general, and oral surgeons, is no greater than the general population, averaging 1%-2%, and is 10 times lower than that for HBV infection. Even more rarely, HCV-infected health care workers have transmitted to patients, and the risk was extremely low-averaging about 0.5%, even for those episodes involving surgeons.

The rate of perinatal transmission of HCV is 4% to 7% per pregnancy and occurs only when HCV RNA is detectable in maternal serum at delivery. Transmission may be related to higher levels (above \(10^7\) copies per mL), although data on the effect of virus concentration have been inconsistent[39]. Prolonged labor after membrane rupture and internal fetal monitoring have been associated with perinatal infection[50,51]. There has been no association with vaginal delivery, caesarian section or breastfeeding. Co-infection with human immunodeficiency virus (HIV) increases the rate of transmission 4- to 5-fold.

The extent to which HCV is transmitted by sexual activity and under what circumstances is one of the most controversial aspects of the epidemiology of hepatitis C. The results of different types of studies have been inconsistent. The strongest evidence for heterosexual activity as a risk factor for HCV infection came from case-control studies of persons with acute non-A, non-B hepatitis (now known as hepatitis C) in the United States during the 1970s and 1980s, which identified sex with an infected partner or with multiple partners as independently associated with acquiring disease[6,7]. Since then, 15%-20% of cases of acute hepatitis C have reported no other risk factor except one of these sexual exposures. In contrast, no association was found with male homosexual activity, and cross-sectional studies conducted since 1990 of men who have sex with men (MSM) and heterosexual persons have documented a higher prevalence of infection among partners of persons with chronic HCV. A similar association with acute hepatitis C and multiple sex partners has been reported from Italy[54], and since 2000, there have been reports from several European countries of episodes of acute hepatitis C among HIV-infected MSM[59,62].

Because of the wide variety of human activities that involve the potential for percutaneous exposure to blood or blood-derived body fluids, there are numerous other biologically-plausible modes of transmission besides those with clearly-demonstrated epidemiologic associations with infection. These include cosmetic procedures (tattooing, body-piercing), intranasal drug use, and religious or cultural practices such as ritual scarification, circumcision, acupuncture, and cupping. In most regions of the world, there are insufficient data to determine whether these risk factors make any measurable contribution to overall HCV transmission. In those countries where adequate studies have been done, none of these activities have been consistently associated with HCV transmission[63].

SUMMARY

Thus, most of the HCV-related disease burden in developed countries has resulted from injection drug use, receipt of transfusions before donor screening, and high-risk sexual activity. In contrast, most of the disease burden in developing countries is related to receipt of unsafe therapeutic injections and contaminated blood. Characterizing the epidemiology of HCV infection in individual countries is crucial to developing and implementing effective preventive measures. In some, ensuring safe blood supplies and health-care related procedures are the highest priorities. In others, priorities need to focus on preventing injecting drug use, improving access to drug treatment, harm reduction counseling, and testing to identify HCV-infected persons for medical evaluation and management.

REFERENCES

The importance of HCV on the burden of chronic liver disease

Sagnelli E

Italy.

C virus: a community-based population study in northern

Med Virol

Community-based seroepidemiological survey of HCV

third millenium: The GEMHEP GenoCII Study.

Peignoux M, Branger M, Rosenberg A, Sogni P, Chaix ML, Pol

Coudé M, Blanchi A, Alain S, Loustaud-Ratti V, Chevallier P,

HCV patients in Belgium.

Evolution over a 10 year period of hepatitis C virus infection in Australia.


Alter MJ. Prevention of spread of hepatitis C. Hepatology 2002; 36: 593-598


Dore GJ. MacDonald M, Law MG, Kaldor JM. Epidemiology of hepatitis C virus infection in Australia. Aust Fam Physician 2003; 32: 796-798


Alter MJ. Epidemiology of hepatitis C. Hepatology 1997; 26: 625-655


Puro V, Petrocillo N, Ippolito G. Risk of hepatitis C
39 Roberts EA, Yeung L. Maternal-infant transmission of hepatitis C virus infection. Hepatology 2002; 36: S106-S113
40 Terrault NA. Sexual activity as a risk factor for hepatitis C. Hepatology 2002; 36: S99-105

S-Editor Liu Y E-Editor Liu Y
www.wignet.com